- €75.15m
- €372.31m
- €786.44m
Brief: Guerbet FY EBITDA Down At 100.7 Million Euros
Brief: Guerbet: Positive Results For Phase III Clinical Trials Of Gadopiclenol
Brief: Guerbet FY Revenue Down At 712.3 Million Euros
Brief: Guerbet: Uk Approves Lipiodol Ultra-Fluid In Women Undergoing Infertility Assessment
Brief: Guerbet Maintains 2020 Objectives Reported With Its Half-Year Results
Brief: Guerbet H1 Operating Income Of 25.4 Million Euros
Brief: Guerbet : Extension Of Indication For Lipiodol Ultra-Fluid Approved By Danish Medicines Agency
Brief: Guerbet End-June Revenue Down At 363.7 Million Euros
Brief: Guerbet To Sell Its Pharmaceutical Site In Montreal To MedXL
Brief: Guerbet: TGA Approves Additional Indication For Lipiodol Ultra-Fluid, Vectorio In Australia
Brief: Guerbet: National Medical Products Administration Approves Lipiodol Ultra-Fluid in China
Brief: Guerbet End-March Revenue Up At 199.2 Million Euros
Brief: Guerbet FY Net Income Down At 37.3 Million Euros
Brief: Guerbet FY Revenue Up At 816.9 Million Euros
Brief: Guerbet Appoints David Hale As CEO As From January 1, 2020
Brief: Guerbet Announces Registration Of Vectorio® In India
Brief: Guerbet Announces Approval For Lipiodol Ultra‐Fluide In Denmark
Brief: Guerbet Partners With Intersystems To Strengthen Deployment Of Contrast&Care
Brief: Guerbet 9-Month Revenue At 603.5 Million Euros